LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Suletud

SektorTervishoid

6.77 -2.31

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.75

Max

7.02

Põhinäitajad
By Trading Economics
Sissetulek	-16M -3.8M
Müük	-31M 45M
P/E Sektori keskmine	14.875 51.415
Aktsiakasum	-0.04
Kasumimarginaal	-8.377
Töötajad	179
EBITDA	-28M -1.3M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-27.75% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-20M 363M
Eelmine avamishind	9.08
Eelmine sulgemishind	6.77

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

3.07 / 3.075 Toetus ja vastupanu

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. mai 2026, 23:10 UTC

Kuumad aktsiad

Stocks to Watch: Agilysys, XP

18. mai 2026, 18:44 UTC

Suurimad hinnamuutused turgudel

Claritev Shares Recover After Comments About DOJ

18. mai 2026, 23:55 UTC

Tulu

Review & Preview: Earnings' Last Gasp -- Barrons.com

18. mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18. mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. mai 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

18. mai 2026, 20:25 UTC

Tulu

Correct: XP 1Q Total Client Assets BRL1.53T

18. mai 2026, 20:23 UTC

Tulu

XP 1Q Total Client Assets BRL1.53B

18. mai 2026, 20:19 UTC

Tulu

XP 1Q Adj EPS BRL2.49 >XP

18. mai 2026, 20:19 UTC

Tulu

XP 1Q Rev BRL4.73B >XP

18. mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18. mai 2026, 19:00 UTC

Tulu

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18. mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18. mai 2026, 18:17 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18. mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18. mai 2026, 16:57 UTC

Omandamised, ülevõtmised, äriostud

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18. mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18. mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18. mai 2026, 16:54 UTC

Omandamised, ülevõtmised, äriostud

Vinci Doesn't Set Out Financial Details of Deal

18. mai 2026, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18. mai 2026, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18. mai 2026, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18. mai 2026, 16:48 UTC

Omandamised, ülevõtmised, äriostud

Vinci Buys Canada's Modern Group of Companies

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-27.75% langus

12 kuu keskmine prognoos

Keskmine 5 USD -27.75%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.